| Patient | Eva Perón |
|---|---|
| Date of birth | 1994-05-07 |
| Identifiers | MRN HR-ML025-SYN; SSN (made up) 000-25-7316 |
| Document date | 2026-11-01 |
| Author | Lucía Barragán, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient with four months of bleeding after intercourse and between periods and tiredness: history in Spanish, speculum examination, a visible cervical mass biopsied, HPV test and cytology, anemia tests, and her wishes about how results are given. Concerns: She has bled after intercourse and between periods for months and is exhausted, and she wants to know the cause; Whatever the results show, she wants to be told the truth herself, in Spanish, before anyone else is told; She wants to keep working and to understand how any treatment would affect her body and her chance of having children. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy | One tablet by mouth once daily | Oral route | 2026-02-09 to 2026-08-17 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day | One or two tablets every 6 hours when needed, no more than 6 a day | Oral route | 2026-02-09 | active | S |
| Nitrofurantoin (monohydrate and macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule twice daily with food for 5 days | Oral route | 2026-03-27 to 2026-03-31 | completed | S |
| Cisplatin 40 mg/m2 (64 mg) intravenous infusion once weekly for five weeks during pelvic radiation, with hydration and antiemetic premedication in the infusion center | 64 mg intravenously once weekly for five doses | Intravenous route | 2026-03-09 to 2026-04-06 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours when needed for nausea in the days after cisplatin | One tablet every 8 hours when needed for nausea | Oral route | 2026-03-09 to 2026-04-10 | completed | S |
| Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than 8 a day | Two capsules after the first loose stool, then one after each, no more than 8 a day | Oral route | 2026-03-09 to 2026-05-04 | completed | S |
| Estradiol 0.1 mg per day transdermal patch, one patch changed twice weekly | One patch changed twice weekly | Topical route | 2026-05-18 | active | S |
| Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiol | One capsule by mouth nightly | Oral route | 2026-05-18 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Punch biopsy of a visible cervical mass at the first visit, with an HPV test and cytology | 2026-02-09 to 2026-02-09 | completed | S |
| Advance care planning conversation, about 18 minutes, in Spanish | 2026-09-21 to 2026-09-21 | completed | S |
| Colposcopy of the cervix and vagina, with pelvic and rectovaginal examination, at the gynecologic oncology consultation | 2026-02-17 to 2026-02-17 | completed | S |
| Pelvic MRI with contrast for staging | 2026-02-23 to 2026-02-23 | completed | S |
| FDG PET-CT from the skull base to mid-thigh for staging | 2026-02-25 to 2026-02-25 | completed | S |
| Pelvic external beam radiation therapy, 45 Gy in 25 fractions by intensity-modulated radiation therapy, with weekly cisplatin | 2026-03-09 to 2026-04-10 | completed | S |
| Image-guided high-dose-rate intracavitary brachytherapy, 28 Gy in 4 weekly fractions | 2026-04-13 to 2026-05-04 | completed | S |
| FDG PET-CT three months after treatment to assess response | 2026-08-10 to 2026-08-10 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-09-21 | Influenza vaccine, 2026-2027 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| January 1950 | Fainting followed by an appendectomy | D (CLM-0003) |
| 1950 | Persistent weakness and anemia from vaginal bleeding after the appendectomy, with further tests delayed | D (CLM-0003) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| She has bled after intercourse and between periods for months and is exhausted, and she wants to know the cause | active | S |
| Whatever the results show, she wants to be told the truth herself, in Spanish, before anyone else is told | active | S |
| She wants to keep working and to understand how any treatment would affect her body and her chance of having children | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 10.4 on 2026-03-27; MCV [Entitic mean volume] in Red Blood Cells by Automated count 77 on 2026-03-02; Leukocytes [#/volume] in Blood by Automated count 4.1 on 2026-03-27; Platelets [#/volume] in Blood by Automated count 168 on 2026-03-27; Ferritin [Mass/volume] in Serum or Plasma 48 on 2026-08-17; Pain severity - 0-10 verbal numeric rating [Score] - Reported 0 on 2026-08-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-21; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-03-27; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 on 2026-03-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-08-17; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 2026-08-17; Neutrophils [#/volume] in Blood by Automated count 2.6 on 2026-03-27; Total score [AUDIT-C] 1 on 2026-09-21; Follitropin [Units/volume] in Serum or Plasma 72 on 2026-05-18; Estradiol (E2) [Mass/volume] in Serum or Plasma 14 on 2026-05-18; Magnesium [Mass/volume] in Serum or Plasma 1.9 on 2026-05-18 [S]
Strengths and supports: Supports: a close friend and a long-time colleague at the foundation; her work gives her purpose. She would like the hospital's spiritual care team offered when she is in treatment [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding after intercourse and between periods, with heavier periods, for about four months, with tiredness and a dull pelvic ache. Never had cervical screening. Speculum examination shows a friable, exophytic mass about 4 cm across on the cervix that bleeds on contact. Punch biopsy, HPV test and cytology taken; urgent gynecologic oncology consultation booked | resolved | confirmed | N93.8 | S — Synthetic presenting problem linked to her documented abnormal bleeding with anemia; superseded by the diagnosis at the consultation. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 9.4 g/dL, mean cell volume 72 fL, ferritin 6 ng/mL, with tiredness and breathlessness on stairs | resolved | confirmed | D50.0 | S — Synthetic modern finding linked to her documented anemia from vaginal bleeding. |
| Invasive squamous cell carcinoma of the cervix, HPV 16 positive: an exophytic tumor about 4.5 cm across with clinical involvement of the left parametrium, not reaching the pelvic wall; pelvic MRI and PET-CT ordered for FIGO 2018 staging. Synthetic modern episode linked to her documented cervical cancer | active | confirmed | C53.9 | S — Synthetic modern diagnosis made at the gynecologic oncology consultation. |
| Acute cystitis during pelvic chemoradiation: two days of new burning, urgency and cloudy urine on top of mild radiation frequency, without fever or flank pain; urine dipstick positive for leukocyte esterase and nitrite; culture grew Escherichia coli sensitive to nitrofurantoin; neutrophil count and kidney function normal; resolved | resolved | confirmed | N30.00 | S — Synthetic acute infection; not a historical claim. |
| Ovarian failure after pelvic radiation, with hot flashes, night sweats, poor sleep and vaginal dryness two weeks after treatment; FSH 72 mIU/mL and estradiol 14 pg/mL | active | confirmed | E89.41 | S — Synthetic expected effect of pelvic chemoradiation. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-09 | Hemoglobin [Mass/volume] in Blood | 9.4 | g/dL | 11.6-15 g/dL | Low | S |
| 2026-02-09 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 72 | fL | 80-100 fL | Low | S |
| 2026-02-09 | Leukocytes [#/volume] in Blood by Automated count | 7.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-09 | Platelets [#/volume] in Blood by Automated count | 398 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-02-09 | Ferritin [Mass/volume] in Serum or Plasma | 6 | ng/mL | A ferritin of 30 ng/mL or less indicates iron deficiency | Low | S |
| 2026-02-09 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S | ||
| 2026-02-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-02-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-02-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 117 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-17 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S | ||
| 2026-02-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-02-17 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-03-02 | Hemoglobin [Mass/volume] in Blood | 10.2 | g/dL | 11.6-15 g/dL | Low | S |
| 2026-03-02 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 77 | fL | 80-100 fL | Low | S |
| 2026-03-02 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-02 | Platelets [#/volume] in Blood by Automated count | 352 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-02 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S | ||
| 2026-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-03-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 2026-05-18 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 11.6-15 g/dL | Low | S |
| 2026-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-18 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S | ||
| 2026-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-05-18 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-08-17 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-08-17 | Ferritin [Mass/volume] in Serum or Plasma | 48 | ng/mL | A ferritin of 30 ng/mL or less indicates iron deficiency | Normal | S |
| 2026-08-17 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 0 | {score} | S | ||
| 2026-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-08-17 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S | ||
| 2026-03-27 | Leukocytes [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-27 | Neutrophils [#/volume] in Blood by Automated count | 2.6 | 10*3/uL | 1.5-7.5 10*3/uL | Normal | S |
| 2026-03-27 | Hemoglobin [Mass/volume] in Blood | 10.4 | g/dL | 11.6-15 g/dL | Low | S |
| 2026-03-27 | Platelets [#/volume] in Blood by Automated count | 168 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-03-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-21 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-05-18 | Follitropin [Units/volume] in Serum or Plasma | 72 | m[IU]/mL | Typical premenopausal follicular-phase range | High | S |
| 2026-05-18 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 14 | pg/mL | Typical premenopausal range | Low | S |
| 2026-05-18 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-09 | Body height | 165 | cm | S |
| 2026-02-09 | Body weight | 53 | kg | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-02-09 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-02-09 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-02-09 | Heart rate | 92 | /min | S |
| 2026-02-09 | Respiratory rate | 16 | /min | S |
| 2026-02-09 | Body temperature | 36.8 | Cel | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-02-17 | Body height | 165 | cm | S |
| 2026-02-17 | Body weight | 52.8 | kg | S |
| 2026-02-17 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 2026-02-17 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-02-17 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-02-17 | Heart rate | 90 | /min | S |
| 2026-02-17 | Respiratory rate | 16 | /min | S |
| 2026-02-17 | Body temperature | 36.7 | Cel | S |
| 2026-02-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-02 | Body height | 165 | cm | S |
| 2026-03-02 | Body weight | 52.5 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 84 | /min | S |
| 2026-03-02 | Respiratory rate | 14 | /min | S |
| 2026-03-02 | Body temperature | 36.7 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-05-18 | Body height | 165 | cm | S |
| 2026-05-18 | Body weight | 50.6 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 18.6 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 80 | /min | S |
| 2026-05-18 | Respiratory rate | 14 | /min | S |
| 2026-05-18 | Body temperature | 36.6 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-17 | Body height | 165 | cm | S |
| 2026-08-17 | Body weight | 52.4 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 74 | /min | S |
| 2026-08-17 | Respiratory rate | 14 | /min | S |
| 2026-08-17 | Body temperature | 36.6 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-27 | Body height | 165 | cm | S |
| 2026-03-27 | Body weight | 51.4 | kg | S |
| 2026-03-27 | Body mass index (BMI) [Ratio] | 18.9 | kg/m2 | S |
| 2026-03-27 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-03-27 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-03-27 | Heart rate | 88 | /min | S |
| 2026-03-27 | Respiratory rate | 16 | /min | S |
| 2026-03-27 | Body temperature | 37.2 | Cel | S |
| 2026-03-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-09-21 | Body height | 165 | cm | S |
| 2026-09-21 | Body weight | 52.8 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 72 | /min | S |
| 2026-09-21 | Respiratory rate | 14 | /min | S |
| 2026-09-21 | Body temperature | 36.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-09 | New patient with four months of bleeding after intercourse and between periods and tiredness: history in Spanish, speculum examination, a visible cervical mass biopsied, HPV test and cytology, anemia tests, and her wishes about how results are given | finished | S |
| 2026-02-17 | Biopsy result given to her in person, and gynecologic oncology consultation the same day: diagnosis, staging plan, treatment options, and fertility and ovarian function counseling | finished | S |
| 2026-03-02 | Staging results (pelvic MRI and PET-CT), FIGO stage, and her treatment and fertility decisions before chemoradiation | finished | S |
| 2026-03-27 | Same-day sick visit for burning on passing urine during chemoradiation | finished | S |
| 2026-05-18 | Review two weeks after completing chemoradiation and brachytherapy: side effects, menopause symptoms, and survivorship care | finished | S |
| 2026-08-17 | Review three months after treatment: PET-CT response, examination, anemia, mood, and the follow-up plan | finished | S |
| 2026-09-21 | Periodic adult preventive visit after cancer treatment | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Diagnosis of a visible cervical lesion: punch biopsy at this visit, an HPV test and cytology, a pregnancy test, a blood count and ferritin; a lesion that looks like cancer is biopsied directly rather than managed by the screening algorithm | completed | GL-ASCCP-2019, GL-NCCN-CERV-2027 | S |
| Urgent gynecologic oncology consultation, on the day the biopsy result is given: diagnosis, staging, treatment by stage, and fertility and ovarian function counseling | completed | GL-NCCN-CERV-2027, GL-ASCO-FP-2018 | S |
| Truthful disclosure as she asked: the biopsy result given to her in person, in Spanish, at a visit with time set aside, before anyone else is told; she chooses who is present and who is told; a professional medical interpreter for clinicians who do not speak Spanish, never a family member; information shared step by step, checking what she wants to know | completed | GL-ASCO-COMM-2017 | S |
| Iron deficiency anemia: ferrous sulfate daily, a blood count at about one month, a ferritin at the end of the course, and acetaminophen rather than anti-inflammatory painkillers for pelvic pain | completed | GL-CMID-2026 | S |
| FIGO 2018 staging: pelvic MRI and FDG PET-CT, kidney function before cisplatin, an HIV test, and an examination of the vagina and parametria | completed | GL-FIGO-2018, GL-NCCN-CERV-2027 | S |
| Fertility and ovarian function counseling before treatment: chemoradiation ends the ability to carry a pregnancy and usually ends ovarian function; egg or embryo freezing (about two weeks), surgical moving of the ovaries out of the radiation field, and a gestational carrier were explained; her decision is recorded | completed | GL-ASCO-FP-2018, GL-NCCN-CERV-2027 | S |
| Psychosocial support: the oncology social worker, the PHQ-9 and GAD-7 at diagnosis, before treatment, at the end of treatment and in follow-up, spiritual care when she asks, and help planning work around treatment | completed | GL-ASCO-ANXDEP-2023, GL-ASCO-COMM-2017 | S |
| Definitive chemoradiation for stage IIB disease: pelvic external beam radiation 45 Gy in 25 fractions with weekly cisplatin 40 mg/m2, then image-guided high-dose-rate brachytherapy, all within eight weeks; weekly blood count, creatinine and magnesium; ondansetron for nausea and loperamide for diarrhea | completed | GL-NCCN-CERV-2027, GL-FIGO-2018 | S |
| Survivorship care: a vaginal dilator three times a week, estradiol with progesterone for radiation-induced menopause until the usual age of menopause, gynecologic oncology review every three months for two years, PET-CT about three months after treatment, and warning symptoms to report | completed | GL-NCCN-CERV-2027 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Diagnosis and stage explained to her directly, in Spanish, with time for questions, before any treatment decision | 2026-03-02 | completed | Diagnosis given to her in person at the second visit and the stage at the third; she made the treatment and fertility decisions herself | S |
| Hemoglobin 10 g/dL or more before radiation begins | 2026-03-02 | completed | Hemoglobin 10.2 g/dL | S |
| Chemoradiation and brachytherapy completed within eight weeks | 2026-05-18 | completed | Completed in eight weeks, with five cisplatin doses | S |
| No evidence of disease on PET-CT and examination three months after treatment | 2026-08-17 | completed | Complete metabolic response; examination without tumor | S |
| PHQ-9 below 5 by six months | 2026-08-17 | completed | PHQ-9 4 | S |